Patents Assigned to Schering Corporation
  • Aspartyl protease inhibitors
    Patent number: 8168641
    Abstract: Disclosed are compounds of formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R1, R2, R6, R7, R30 and R31 are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: May 1, 2012
    Assignee: Schering Corporation
    Inventors: Yusheng Wu, Ulrich Iserloh, Jared N. Cumming, Xiaoxiang Liu, Robert D. Mazzola, Zhong-Yue Sun, Ying Huang, Andrew Stamford, Brian McKittrick, Zhaoning Zhu
  • AGGLOMERATE FORMULATIONS INCLUDING ACTIVE PHARMACEUTICAL AGENTS WITH TARGETED PARTICLE SIZES
    Publication number: 20120097160
    Abstract: Various embodiments of the present invention provide for an agglomerate comprising at least one active pharmaceutical agent and at least one excipient; wherein at least about ninety percent of the at least one active pharmaceutical agent have a particle size of less than about 2 ?m.
    Type: Application
    Filed: April 23, 2010
    Publication date: April 26, 2012
    Applicant: SCHERING CORPORATION
    Inventors: Preetanshu Pandy, Sai Prasanth Chamarthy, Jennifer Lynn Wylie
  • AGGLOMERATE FORMULATIONS USEFUL IN DRY POWDER INHALERS
    Publication number: 20120101077
    Abstract: Several embodiments of the present invention provide for an agglomerate useful for an agglomerate based dry powder inhaler comprising at least one active pharmaceutical agent, at least one additional functional excipient and at least one excipient, such as a binder. Useful at least one additional functional excipients include but are not limited to magnesium stearate, colloidal silica, silicon dioxide, sucrose stearate, L-leucine and combinations thereof.
    Type: Application
    Filed: April 23, 2010
    Publication date: April 26, 2012
    Applicant: Schering Corporation
    Inventors: Preetanshu Pandy, Sai Prasanth Chamarthy, Brent Ashley Donovan
  • Process for preparing (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
    Patent number: 8163937
    Abstract: The present invention relates also to a process for the preparation of intermediate compounds useful in preparing the compounds of Formula (I) using the process of Scheme (II).
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: April 24, 2012
    Assignee: Schering Corporation
    Inventors: George S. K. Wong, Hong-Chang Lee, Jennifer A. Vance, Weidong Tong, Tetsuo Iwama
  • MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS
    Publication number: 20120094937
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: December 20, 2011
    Publication date: April 19, 2012
    Applicant: Schering Corporation
    Inventors: Daniel M. Gorman, Troy D. Randall, Albert Zlotnik
  • Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds utilizing bisulfite intermediate
    Patent number: 8158807
    Abstract: The present invention provides for a process for preparing 6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-2-sulfonate, an intermediate useful in the efficient preparation of (1R,2S,5S)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylic acid and esters and salts thereof, processes for preparing (1R,2S,5S)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylic acid and esters and salts thereof from the sulfonate intermediate and processes for preparing 6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-2-sulfonate.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: April 17, 2012
    Assignee: Schering Corporation
    Inventors: Thierry Berranger, Patrice Demonchaux
  • Anti-MDL-1 antibodies
    Patent number: 8153134
    Abstract: Antibodies to human MDL-1 are provided, as well as uses thereof, e.g., in treatment of immune disorders, in particular, infectious diseases and sepsis.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: April 10, 2012
    Assignee: Schering Corporation
    Inventors: Michael E. Bigler, Paul G. Heyworth, Joseph H. Phillips, Leonard G. Presta
  • Bicyclic and tricyclic derivatives as thrombin receptor antagonists
    Patent number: 8153664
    Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: April 10, 2012
    Assignee: Schering Corporation
    Inventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yuguang Wang, Yan Xia
  • NPC1L1 ORTHOLOGUES
    Publication number: 20120084871
    Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.
    Type: Application
    Filed: February 14, 2011
    Publication date: April 5, 2012
    Applicant: Schering Corporation
    Inventors: Scott Altmann, Xiaorui Yao, Kim Anne O'Neill, Brian E. Hawes
  • Heterocyclic compounds as factor IXA inhibitors
    Patent number: 8148363
    Abstract: The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: April 3, 2012
    Assignee: Schering Corporation
    Inventors: Martin C. Clasby, William J. Greenlee, Yan Xia, Tin-Yau Chan, Mariappan V. Chelliah, Samuel Chackalamannil, Haiyan Pu, Keith A. Eagen, Henry Vaccaro, Brian A. McKittrick, Liyuan Wang, Xiaobang Gao
  • Nucleic acid encoding TNFx protein
    Patent number: 8148507
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: April 3, 2012
    Assignee: Schering Corporation
    Inventors: Christi L. Parham, Daniel M. Gorman, Hirokazu Kurata, Naoko Arai, Theodore R. Sana, Jeanine D. Mattson, Erin E. Murphy, Chetan Savkoor, Jeffery Grein, Kathleen M. Smith, Terrill K. McClanahan
  • NPC1L1 (NPC3) AND METHODS OF USE THEREOF
    Publication number: 20120079616
    Abstract: The present invention provides human, rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.
    Type: Application
    Filed: October 12, 2011
    Publication date: March 29, 2012
    Applicant: Schering Corporation
    Inventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
  • 2,3-substituted indole derivatives for treating viral infections
    Patent number: 8143305
    Abstract: The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 27, 2012
    Assignee: Schering Corporation
    Inventors: Gopinadhan N. Anilkumar, Frank Bennett, Tin-Yau Chan, Kevin X. Chen, Mousumi Sannigrahi, Francisco Velazquez, Srikanth Venkatraman, Qingbei Zeng, Jose S. Duca, Charles A. Lesburg, Joseph A. Kozlowski, F. George Njoroge, Stuart B. Rosenblum, Neng-Yang Shih, Stephen J. Gavalas, Yueheng Jiang, Patrick A. Pinto, Haiyan Pu, Oleg B. Selyutin, Bancha Vibulbhan, Li Wang, Wanli Wu, Weiying Yang, Yuhua Huang, Hsueh-Cheng Huang, Robert Palermo, Boris Feld
  • Mammalian expression vector pUHAB
    Patent number: 8137933
    Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: March 20, 2012
    Assignee: Schering Corporation
    Inventor: Deba P. Saha
  • Exo-selective synthesis of himbacine analogs
    Patent number: 8138180
    Abstract: This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the chiral carbamate ester route. The compounds produced thereby are useful as thrombin receptor antagonists.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: March 20, 2012
    Assignee: Schering Corporation
    Inventors: Tiruvettipuram K. Thiruvengadam, Anantha Sudhakar, Ngiap Kie Lim, Daw-long Kwok, George G. Wu, Tao Wang, Mingsheng Huang, Michael D. Green
  • Antibodies and functional fragments thereof that specifically bind an RF-amide peptide or a precursor thereof
    Patent number: 8133980
    Abstract: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: March 13, 2012
    Assignee: Schering Corporation
    Inventors: Ying Jiang, Fang Liang Zhang, Nicholas J. Murgolo, Lin Luo, Jason S. Simon
  • STABLE PHARMACEUTICAL DRUG PRODUCTS
    Publication number: 20120055469
    Abstract: Various aspects of the present invention provide for methods of manufacturing a pharmaceutical drug product, which include storing a container at a temperature greater than ambient conditions for at least about seven days and conducting release testing on the container after storing. Products manufactured by this method have a more consistent fine particle size distribution (FSD) and fine particle fraction (FPF) at ambient conditions and at accelerated stability conditions over the life of the drug product. Advantageously, such products may more reliably and regularly pass testing requirements as required for an approved drug product by regulatory authorities such as the United States Food and Drug Administration (USFDA).
    Type: Application
    Filed: November 16, 2011
    Publication date: March 8, 2012
    Applicant: Schering Corporation
    Inventors: JILL K. SHERWOOD, Joel Sequeira, Brent Ashley Donovan
  • PROCESSES OF MAKING AND USING PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS
    Publication number: 20120053219
    Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
    Type: Application
    Filed: November 7, 2011
    Publication date: March 1, 2012
    Applicant: Schering Corporation
    Inventors: Sydney Ugwu, Vinay Radhakrishnan, Peter M. Ihnat, Leonore C. Witchey-Lakshmanan
  • USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS
    Publication number: 20120052044
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Application
    Filed: November 1, 2011
    Publication date: March 1, 2012
    Applicant: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: RE43298
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: April 3, 2012
    Assignees: Schering Corporation, Dendreon Corporation
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry M. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang